Non-insulin Therapies for Diabetes Market Global Industry Outlook, Latest Trends and Forecast to 2030
Global non-insulin therapies for diabetes market was valued at US$ 61,090.1 million in 2018 and is estimated to reach US$ 105,461.5 million by 2027, growing at a CAGR of 6.3% over the forecast period. Major industry participants in global non-insulin therapies for diabetes market include Eli Lilly and Company, Eurofarma Laboratorios S.A., GlaxoSmithKline plc, Merck Sharp & Dohme Corp. (subsidiary of Merck & Co., Inc), Novo Nordisk, Luye Pharma Group, and Pfizer Inc. among others. New product launches, merger and acquisition, geographical expansion are some of the major strategies adopted by these players to gain a competitive edge.
Download Sample PDF For Business Information: https://www.absolutemarketsinsights.com/request_sample.php?id=259&rp
Increasing demand for combination therapy and rapid advancements in diabetes treatment are fueling the global non-insulin therapies for diabetes market growth. Combination therapies such as administration of anti-hyperglycemic drugs alone or in combination with insulin used for the treatment of type 2 diabetes. Moreover, from the demand side, surge in people suffering from type 2 diabetes happens to be the primary reason behind growing adoption of various non-insulin therapies across the globe.
As per International Diabetes Foundation (IDF), in 2017, the global prevalence of diabetic patients stood at 425 million, of which 400 million were suffering from type 2 diabetes. Moreover, according to the World Health Organization (WHO), in 2017, diabetes was among top three cause of death with more than 30 million cases in the U.S. alone.
Technological advancements expected to be key growth enabler in the non-insulin therapies for diabetes market. Key vendors operating in the market developed technology platforms such as protein oral delivery (POD) technology (Oramed Pharmaceuticals), Eligen (Emisphere Technologies), Axcess (Diabetology), and PharmFilm Technology (MonoSol Rx) for oral administration of GLP-1 agonists. Moreover, companies such as Panacea and ScinoPharm are in the early stage development of oral capsules for the DPP4 inhibitors.
Market Segmentation:
- By Product
- Oral
- Thiazolidinediones (TZDs)
- Insulin secretagogues
- Alpha-glucosidase inhibitors (AGIs)
- Sulfonylureas
- Dipeptidyl peptidase-4 (DPP-4) inhibitors
- Sodium-glucose cotransporter-2 (SGLT2) inhibitors
- Glinides/Meglitinides
- Metformin
- Biguanides
- Others
- Injectable
- Glucagon-like peptide-1 (GLP-1) agonists
- Amylin Agonists
- Others
- By Distributor
- Hospital Pharmacy
- Retail Pharmacies
- Online Pharmacy
- Others
- By Geography
- North America
- U.S.
- Canada
- Mexico
- Rest of North America
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Argentina
- Brazil
- Rest of Latin America
Non-insulin Therapies for Diabetes Market research added by Absolute Markets Insights, offers a comprehensive analysis of the growth trends prevailing in the global business arena. This report also provides definitive data regarding the market, size, marketing aspects, and revenue forecast of the industry. In addition, the study explicitly highlights the competitive status of major players in the projection schedule while focusing on their portfolio and regional expansion efforts.
The Global Non-insulin Therapies for Diabetes Market Analysis to 2030 is a specialized and in-depth study of the Technology, Media, and Telecommunications industry, with an emphasis especially on the analysis of global market trends. The report aims to provide an overview of the enterprise content delivery networks and enterprise streaming software market with detailed market segmentation by component, type of deployment, industry vertical, and geography. The global market for enterprise content delivery networks and enterprise streaming software is expected to witness high growth during the forecast period.
Financial performance:
The overall turnover of the companies / segments for the years 2021, 2020 and 2019 is provided in the sub-heading “Financial performance” (listed companies) with the analysis and explanation of the increase or decrease. decrease in these due to factors such as mergers and acquisitions, profit or loss of any strategic business unit (SBU) and others.
Strategic initiatives:
Information relating to new product launches, strategic collaboration, mergers and acquisitions, regulatory approval and other company developments in the market is covered in the strategic initiatives section.
Non-insulin Therapies for Diabetes Market: Regional analysis includes:
- Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia and Australia)
- Europe (Turkey, Germany, Russia UK, Italy, France, etc.)
- North America (United States, Mexico and Canada.)
- South America (Brazil etc.)
- The Middle East and Africa (GCC countries and Egypt.)
This research provides detailed information on the major factors influencing the Non-insulin Therapies for Diabetes market growth on a global and regional level (drivers, restraints, opportunities and challenges), forecast of market size, in terms of value, market share by region and segment; regional market positions; growth opportunities by segment and by country, strengths and weaknesses, brand portfolio; Marketing and distribution strategies; challenges and threats of current competition and prospects; Key Company Profiles, SWOTs and Growth Strategies.
The Non-insulin Therapies for Diabetes market research covers a comprehensive analysis of the following data:
• Historical and future growth of the Global Non-insulin Therapies for Diabetes market.
• Segmentation of enterprise content delivery network and enterprise streaming software market to highlight the growth prospects and trends impacting these segments.
• Change the consumption behavior of customers in different regions.
• Regional analysis on the basis of market share, growth prospects and key countries.
• Agreements, product launches, acquisitions and R&D projects of various players in the enterprise content delivery networks and enterprise streaming software market.
Get More Information : https://www.absolutemarketsinsights.com/reports/Global-Non-insulin-Therapies-for-Diabetes-Market-2019-2027-259
Contact Us:
Company: Absolute Markets Insights
Email Id: sales@absolutemarketsinsights.com
Phone: IN +91-740-024-2424, US +1-510-420-1213
Contact Name: Shreyas Tanna
Website: www.absolutemarketsinsights.com
